Bridgebio Q2 2023 Earnings Report
Key Takeaways
BridgeBio Pharma reported positive Phase 3 ATTRibute-CM study results for acoramidis and plans to file an NDA with the FDA by the end of 2023. They ended the quarter with $353 million in cash, cash equivalents, marketable securities, and short-term restricted cash, providing runway into 2H 2024.
Announced positive results from the Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM patients, with a highly statistically significant result on the primary endpoint.
Presented updated six-month results from Cohort 5 of PROPEL2, a Phase 2 trial of infigratinib in children with achondroplasia.
Dosed the first participant in FORTIFY, a global Phase 3 study of BBP-418 in patients with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
Three lead KRAS programs are advancing, with an Investigational New Drug (IND) application planned for first-in-class direct KRASG12C (ON) inhibitor BBO-8520 in 2023.
Bridgebio
Bridgebio
Bridgebio Revenue by Segment
Forward Guidance
BridgeBio anticipates $300-$350 million of investment will support acoramidis from here through the first 12 months of commercial launch.